Company: ZLAB
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0001628280-25-018384
Chunk: 56

Company: Zai Lab Ltd
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 56
---
 BLA for efgartigimod for CIDP; and submission of an Investigational New Drug (“IND”) application to the FDA and CTA to the NMPA for ZL-1310, our DLL3 ADC for neuroendocrine tumors .

#### Research (Score: 5.0%; Target: 10.0%)
Goals: Complete an IND-enabling study and select new clinical product candidates

Achievements: Although the Company did not file an IND, we nominated two pre-clinical candidates.

### Business Development (Score: 16.9%; Target: 15.0%)
Goals: Establish strategic relationships and explore business development opportunities, including transformative, global, and regional deals

Achievements: The Company entered into several synergistic business development arrangements in 2024, including a global deal for a pre-clinical LRRC15 ADC with MediLink, a regional deal with Vertex Pharmaceuticals Inc. for poveticept, a regional deal with Zenas for ZL-1108, and a strategic collaboration with Pfizer to support the launch of XACDURO in China.

#### Commercial (Score: 30.0%; Target: 30.0%)
Goals: Achieve total revenue and commercial profitability goals

Achievements: Although the Company did not achieve its total revenue goal, it achieved strong year-over-year revenue growth of 50%, and the Company’s increase in commercial profit (calculated as net product revenue less cost of sales and sales and marketing expenses for our commercial products) significantly exceeded its commercial profitability goal.

#### Corporate Functions (Score: 17.0%; Target: 15.0%)
Goals: Deliver operating profit target; execute capital strategy, such as to meet working capital needs; operate within budget; continue to drive efficiency and productivity; and achieve other corporate, functional, HR, IT, ESG, legal, and compliance objectives

<div align='center'>-41-</div>

Achievements: The Company exceeded operating target goals, with operating expenses significantly below budget driven by our focus on increased efficiency and productivity; successfully executed on its capital strategy, ending the year with a strong cash and cash equivalents balance of $790.2 million; continued to deliver on its ESG goals; uplifted business operation efficiency; and efficiently supported corporate needs, including with respect to human capital needs and talent development and legal and compliance objectives.

The Compensation Committee also considered the Company’s capital raising efforts as an additional achievement that was above and beyond the development goals approved by the Compensation